Quality of life study for Fabry disease patients aged 65+
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study looks at the quality of life of people aged 65 and older with Fabry disease. It includes patients who are receiving specific treatment and those who are not, to compare their experiences.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 years or older.
- You must have a confirmed diagnosis of Fabry disease.
- You need to have had certain heart and kidney tests (like an ECG, 24-hour heart monitor, heart ultrasound, and urine or blood tests for kidney function).
- You must be able to understand the study information and agree to take part.
- You need to be covered by a social security plan (but not emergency medical assistance for non-residents).
- You cannot be in legal guardianship or under any form of detention.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how Fabry disease affects daily life in adults who haven't started treatment yet. Researchers want to understand your experiences and challenges to improve care for people with this rare genetic condition.
This study observes how well the medication pegunigalsidase alfa works over a long period in people with Fabry disease. It helps doctors learn more about managing the condition in everyday life.
This trial tests whether agalsidase alfa can reduce heart inflammation in people with Fabry disease who have heart problems. You may qualify if you have not had this treatment in the past year.
This study is looking at how to improve the care and follow-up for people with Fabry's disease, a rare genetic disorder. It aims to create a better care pathway to help patients manage their condition.
This study tests an enzyme replacement therapy (agalsidase alfa) for Fabry disease in Chinese children and adults. It's an observational study that follows patients who receive the treatment as part of their regular care.
This study looks at how well available Fabry disease treatments (like migalastat or ERT) work over time in real life. It may help doctors understand who benefits most from these medicines.
Hear when a new Fabry Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.